Aura Biosciences, a portfolio company of biotech venture capital firm Ysios Capital, has priced its IPO and is now trading on the NASDAQ. This marks the third Ysios Capital portfolio company to list on the NASDAQ, after LAVA Therapeutics and CVRx Inc.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.